Navigation Links
Echo Therapeutics to Present at the LifeTech Capital 1st Annual Miami Medical Investors Conference
Date:10/29/2010

FRANKLIN, Mass., Oct. 29 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the LifeTech Capital 1st Annual Miami Medical Investors Conference being held November 12, 2010 at the JW Marriott Marquis in Miami, Fl. The Company's presentation is scheduled for 11 a.m. ET. Management will be available during the day on November 12 for one-on-one meetings.

In addition, Dr. Mooney has been selected to appear on the "Innovations in Science & Industry" panel with the leading medical researchers from the University of Miami Miller School of Medicine. The panel discussion will take place at 8:30 a.m. on November 12.  

The LifeTech Capital Miami Medical Investors Conference brings together promising biotechnology companies, medical and scientific key opinion leaders with institutional and accredited investors from across the country. More information can be found at http://www.LifeTechCapital.com/conference

About Echo TherapeuticsEcho is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2009, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.For More Information:Patrick T. Mooney, M.D.

Jeffrey Stanlis

Media: Richard SternChairman and Chief Executive Officer

Partner, Hayden IR

Stern & Co.(508) 530-0329

(602) 476-1821

(212) 888-0044
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
2. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
3. Columbia University Students Learn About Pharmacy Benefit Management From Prime Therapeutics President and CEO
4. Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call
5. Cell Therapeutics Third Quarter Net Loss Decreases by 68% in 2010 Compared to 2009
6. Veteran Pharmaceutical Executives Form New American Therapeutics, Inc.
7. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
8. Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology
9. Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
10. Algeta and Lumiphore Announce Global Agreement for the Development of Targeted Alpha-Pharmaceutical Therapeutics
11. BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
(Date:4/27/2016)... 27, 2016 Tie-up with Government ... to save newborns   Fortis La ... newborns in collaboration with Breast Milk Foundation (BMF), a non-profit ... Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre ... for infants and should be available to babies deprived of ...
(Date:4/27/2016)... NEW YORK , April 27, 2016 /PRNewswire/ ... OASM ), a developer of a new ... today announced positive overall survival results for Paclical/Apealea ... total of 789 patients with epithelial ovarian cancer. ... treatment groups: Paclical/Apealea in combination with carboplatin versus ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Saturday, April 30, marks World ... on public health. The World Veterinary Association (WVA) and the World Organization for ... continuing education with a One Health focus, which emphasizes how veterinarians pursue continuing ...
(Date:4/30/2016)... ... ... for all of us, but there are things we can do to improve the odds of ... more and more that there are simple, yet important steps that can be taken to maintain ... Kohli’s recommends for her patients include;, , exercise , ...
(Date:4/29/2016)... (PRWEB) , ... April 30, 2016 , ... Mercy College ... campus. The following programs will be expanding due to high demand: Master of ... The expansion will begin this summer. , School of Business Graduate Program ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation for ... first accreditation of three residency programs that Memorial is currently pursuing, including Pediatrics ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... On Tuesday, ... hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, ... Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations ...
Breaking Medicine News(10 mins):